Glycation impairs high-density lipoprotein function

Diabetologia

Volumn 43, Issue 3, 2000, Pages 312-320

  Hedrick, C C ^a   Thorpe, S R ^b   Fu, M X ^b   Harper, C M ^d   Yoo, J ^c   Kim, S M ^c   Wong, H ^c   Peters, A L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCLA Division of Cardiology ^*

Author keywords

Apolipoprotein AI; Apolipoprotein AII; Hepatic lipase; High density lipoprotein; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLDIALKYLPHOSPHATASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LYSINE DERIVATIVE;

AORTA; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CONTROLLED STUDY; DIABETOGENESIS; ENDOTHELIUM CELL; GLYCATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0034062591     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050049     Document Type: Article

References (46)

1. 1. Karathanasis SK (1992) Lipoprotein metabolism: high-density lipoprotein. In: Lusis AJ, Rotter JI, Sparkes RS (eds) Monographs in Human Genetics: Molecular Genetics of Coronary Artery Disease. Karger, Basel, pp 140-171
2. 2. Miller NE (1987) Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113: 589-597
3. 3. Navab M, Imes SS, Hough GP et al. (1991) Monocyte transmigration induced by modification of LDL in cocultures of human aortic endothelial cells is due to induction of MCP-1 synthesis and is abolished by HDL. J Clin Invest 88: 2039-2046
4. 4. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 286: 152-154
5. 5. Watson AD, Berliner JA, Hama SY et al. (1995) Protective effect of high-density lipoprotein associated PON. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882-2891
6. 6. Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598-608
7. 7. Ruiz J, Blanche H, James RW et al. (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in Type 2 diabetes. Lancet 346: 869-872
8. 8. Rao SN, Cortese C, Miller NE, Levy Y, Lewis B (1982) Effects of heparin infusion on plasma lipoproteins in subjects with lipoprotein lipase deficiency. Evidence for a role of hepatic endothelial lipase in the metabolism of HDL subfractions in man. FEBS Lett 150: 255-259
9. 9. Brinton EA, Eisenberg S, Breslow JL (1994) Human HDL cholesterol levels are determined by apoAI fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14: 707-720
10. 2 subfraction with hepatic lipase. J Lipid Res 33: 1269-1272
11. 3 for hepatic lipase. Arterioscler Thromb Vasc Biol 16: 755-762
12. 12. Riemens S, van Tol A, Sluiter W, Dullaart R (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apoB-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140: 71-79
13. 13. Syvanne M, Ahola M, Lahdenpera S et al. (1995) High density lipoprotein subfractions in non-insulin dependent diabetes mellitus and coronary artery disease. J Lipid Res 36: 573-582
14. 14. Thulaseedharan N, Augusti KT (1995) Risk factors for coronary heart disease in noninsulin-dependent diabetes. Indian Heart J 47: 471-476
15. 15. Ruderman NB, Williamson, JR, Brownlee M (1992) Glucose and diabetic vascular disease. FASEB J 6: 2905-2914
16. 16. Rabini RA, Fumelli P, Galassi R et al. (1994) Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism 43: 1470-1474
17. 17. Lyons TJ, Jenkins AJ (1997) Glycation, oxidation, and lipidoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 5: 365-391
18. 18. Kim JA, Berliner JA, Natarajan RD, Nadler JL (1994) Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 43: 1103-1107
19. 19. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long standing IDDM. Diabetes 41: 1286-1292
20. 20. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ (1993) Increased collagen-linked pentosidine levels and advanced glycation endproducts in early diabetic nephropathy. J Clin Invest 92: 212-217
21. 21. McCance DR, Dyer DG, Dunn JA et al. (1993) Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus. J Clin Invest 92: 2470-2478
22. 22. Cohen MP (1986) Diabetes and protein glycosylation: measurement and biological relevance. Springer, Berlin Heidelberg New York
23. 23. Duell PB, Oram JF, Bierman EL (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor mediated cholesterol efflux. Diabetes 40: 377-384
24. 24. O K, Hill JS, Pritchard PH (1995) Role of n-linked glycosylation of LCAT in lipoprotein substrate specificity. Biochem Biophys Acta 1254: 193-197
25. 25. Fievet C, Igau B, Bresson R, Drouin P, Fruchart JC (1995) Non-enzymatic glycation of apolipoprotein AI and its functional consequences. Diabetes Metab 21: 95-98
26. 26. Burstein M, Scholnick HR, Morfin R (1970) Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11: 583-595
27. 27. Navab M, Hama-Levy S, Van Lenten BJ et al. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99: 2005-2019
28. 28. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ (1993) Influence of mouse apolipoprotein AII on plasma lipoproteins in transgenic mice. J Biol Chem 268: 20676-20682
29. 29. Knecht KJ, Dunn JA, McFarland KF et al. (1991) Oxidative degradation of glycated proteins: effects of diabetes and aging on N-carboxymethyl)lysine levels in human urine. Diabetes 40: 190-196
30. 30. Zhang A, Vertommen J, Van Gaal L, De Leeuw I (1994) A rapid and simple method for measuring the susceptibility of low-density lipoprotein and very low density lipoprotein to copper-catalyzed oxidation. Clin Chim Acta 227: 159-173
31. 31. McDowell IF, McEneny J, Trimble ER (1995) A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. Ann Clin Biochem 32: 167-174
32. 32. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ (1993) Atherosclerosis in transgenic mice overexpressing apolipoprotein AII. Science 261: 469-472
33. 33. Watson AD, Leitinger N, Navab M et al. (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 272: 13597-13607
34. 34. Pawlowski NA, Abraham EL, Pointer S, Scott WA, Cohen ZA (1985) Human monocyte:endothelial cell interaction in vitro. Proc Natl Acad Sci USA 82: 8208-8212
35. 35. Fogelman AM, Sykes K, Van Lenten BJ, Territo MC, Berliner JA (1988) Modification of the Recalde method for the isolation of human monocytes. J Lipid Res 29: 1243-1247
36. e(carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986
37. 37. Cushing SD, Berliner JA, Valente AJ et al. (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134-5138
38. 38. Tkac I, Kimball BP, Lewis G, Uffleman K, Steiner G (1997) The severity of coronary atherosclerosis in Type 2 diabetes mellitus is related to the number of circulating triglyceriderich lipoprotein particles. Arterioscler Thromb Vasc Biol 17: 3633-3638
39. 39. Lyons TJ (1995) Glycation, oxidation, and glycoxidation reactions in the development of diabetic complications. Contrib Nephrol 112: 1-10
40. 40. Baynes JW (1991) Role of oxidative stress in the development of diabetic complications. Diabetes 40: 405-412
41. 41. Wells-Knecht MC, Thorpe SR, Baynes JW (1995) Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 34: 15134-15141
42. 42. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995) N-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878
43. 43. Aviram M, Billecke S, Sorenson R et al. (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18: 1617-1624
44. 44. Mackness B, Mackness MI, Arrol S et al. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139: 341-349
45. 45. Pfohl M, Koch M, Enderle MD et al. (1999) Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48: 623-627
46. 46. Garin MC, James RW, Dussoix P et al. (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66